Abstracts at AUGS/IUGA Scientific Meeting affirm leva's treatment value for female urinary incontinence 8 weeks of treatment with leva delivers symptom improvement for one year: real-world data establishes efficacy outside of a research setting AUSTIN, Texas, June 17,...

Journal of the American College of Obstetricians and Gynecologists (ACOG) publishes randomized controlled superiority trial showing leva's efficacy in treating UI vs. performing Kegels alone.     BOSTON, March 11, 2022 /PRNewswire/ -- Renovia Inc....

BOSTON, March 7, 2022  /PRNewswire/ -- Renovia Inc. ("Renovia"), a women-led company that develops digital therapeutics for female pelvic floor disorders, announced today that Capital Women's Care is recommending the leva® Pelvic Health System to its patients who...

The Healthcare Technology Report is pleased to announce The Top 25 Women Leaders in Medical Devices of 2022. With the medical device industry advancing at an unprecedented rate, new and exciting developments in robotics, materials science, analytics, and other...

Global award for Research and Development recognizes Renovia's commitment to generating the highest quality data supporting leva as effective treatment for urinary incontinence   BOSTON, Jan. 6, 2022 /PRNewswire/ -- Renovia Inc. ("Renovia"), a women-led company that...

BOSTON, Dec. 21, 2021 /PRNewswire/ -- Renovia Inc. ("Renovia"), a women-led company that develops digital therapeutics for female pelvic floor disorders, today announced that Neurourology and Urodynamics, the official journal of the Society for Urodynamics &...

Boston, Mass—October 29, 2021—Renovia Inc. (“Renovia”), a women-led company that develops digital therapeutics for female pelvic floor disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the leva®...

For immediate release:  Aligns with #PFDWeek, which spotlights pelvic floor health in women  Charleston, SC—October 12, 2021—The National Association for Continence (NAFC), the nation’s leading advocate for people living with bladder and bowel disorders, announced...

Renovia's leva® Pelvic Health System is First Femtech Offering Included in Product Library of Digital Therapeutics Alliance Prestigious distinction is further evidence that leva® Pelvic Health System meets rigorous standards for high-quality, evidence-based patient...

Meet The Company Offering An Innovative Medication-Free Approach To Better Pelvic Floor Health, Bringing Female Urinary Incontinence Out Of The Closet Marija Butkovic 12:26am EDT ForbesWomen I write about innovative tech companies and women behind them. Almost 50% of...

Study shows leva® Digital Therapeutic improves fecal incontinence symptoms Women with accidental bowel leakage experience "significant improvement" in 10-week study NEWS PROVIDED BY Renovia May 25, 2021, 09:00 ET BOSTON, May 25, 2021 /PRNewswire/ -- Renovia Inc....

Renovia raises $17M in Series C-1 financing Proceeds to advance U.S. commercial launch of leva® Digital Therapeutic and additional clinical development Renovia Inc. Apr 19, 2021, 09:00 ET BOSTON, April 19, 2021 /PRNewswire/ -- Renovia Inc. ("Renovia"), a women-led...

Renovia names new president and CEO; completes enrollment for randomized controlled trial Women-led team achieves key milestone ahead of schedule Boston, Mass.—January 19, 2021—Renovia Inc. (“Renovia”), a women-led company that develops digital therapeutics for female...

Renovia presents at Piper Sandler Healthcare Conference Medical Technology Disruptors Panel includes Renovia’s leva® Digital Therapeutic, a novel approach for an underreported disorder affecting 20 million women in the U.S. Boston, Mass.—December 1, 2020—Renovia Inc....

Boston, MA – November 25, 2019 – Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic device and app technologies for women with pelvic floor disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the next-generation leva® Pelvic Digital Therapeutic for the strengthening of pelvic floor muscles and the treatment of stress, mixed and mild to moderate urgency urinary incontinence (UI) in women.

Study Demonstrates Improvements in Objective Pelvic Floor Muscle Measures, Patient-Reported Urinary Incontinence Severity and Condition-Specific Quality of Life, with Results Evident after 1 Week of Use